{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:44:44Z","timestamp":1792806284703,"version":"4.5.0"},"reference-count":277,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1038\/s41582-020-0330-x","type":"journal-article","created":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T15:03:04Z","timestamp":1584975784000},"page":"213-228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["Development of disease-modifying drugs for frontotemporal dementia spectrum disorders"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7220-0656","authenticated-orcid":false,"given":"Francesco","family":"Panza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madia","family":"Lozupone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Seripa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Watling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Giannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0327-7262","authenticated-orcid":false,"given":"Bruno P.","family":"Imbimbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,23]]},"reference":[{"key":"330_CR1","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S0140-6736(15)00461-4","volume":"386","author":"J Bang","year":"2015","unstructured":"Bang, J., Spina, S. & Miller, B. L. Frontotemporal dementia. Lancet 386, 1672\u20131682 (2015).","journal-title":"Lancet"},{"key":"330_CR2","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1212\/WNL.0000000000002638","volume":"86","author":"IT Coyle-Gilchrist","year":"2016","unstructured":"Coyle-Gilchrist, I. T. et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology 86, 1736\u20131743 (2016).","journal-title":"Neurology"},{"key":"330_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/jnc.13640","volume":"138","author":"RM Tsai","year":"2016","unstructured":"Tsai, R. M. & Boxer, A. L. Therapy and clinical trials in frontotemporal dementia: past, present, and future. J. Neurochem. 138, 211\u2013221 (2016).","journal-title":"J. Neurochem."},{"key":"330_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/2045125317739818","volume":"8","author":"JJ Young","year":"2018","unstructured":"Young, J. J. et al. Frontotemporal dementia: latest evidence and clinical implications. Ther. Adv. Psychopharmacol. 8, 33\u201348 (2018).","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"330_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","volume":"15","author":"F Panza","year":"2019","unstructured":"Panza, F. et al. A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 15, 73\u201388 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"330_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3109\/15622975.2010.538083","volume":"12","author":"R Ihl","year":"2011","unstructured":"Ihl, R. et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer\u2019s disease and other dementias. World J. Biol. Psychiatry 12, 2\u201332 (2011).","journal-title":"World J. Biol. Psychiatry"},{"key":"330_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1212\/01.wnl.0000191304.55196.4d","volume":"66","author":"ED Huey","year":"2006","unstructured":"Huey, E. D., Putnam, K. T. & Grafman, J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 66, 17\u201322 (2006).","journal-title":"Neurology"},{"key":"330_CR8","first-page":"CD009444","volume":"3","author":"Y Li","year":"2015","unstructured":"Li, Y. et al. Cholinesterase inhibitors for rarer dementias associated with neurological conditions. Cochrane Database Syst. Rev. 3, CD009444 (2015).","journal-title":"Cochrane Database Syst. Rev."},{"key":"330_CR9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/0891988717700506","volume":"30","author":"M Buoli","year":"2017","unstructured":"Buoli, M. et al. Pharmacological management of psychiatric symptoms in frontotemporal dementia: a systematic review. J. Geriatr. Psychiatry Neurol. 30, 162\u2013169 (2017).","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"330_CR10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/0269881116680924","volume":"31","author":"JT O\u2019Brien","year":"2017","unstructured":"O\u2019Brien, J. T. et al. Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. J. Psychopharmacol. 31, 147\u2013166 (2017).","journal-title":"J. Psychopharmacol."},{"key":"330_CR11","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2165\/00002512-200421140-00003","volume":"21","author":"R Moretti","year":"2019","unstructured":"Moretti, R. et al. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging 21, 931\u2013937 (2019).","journal-title":"Drugs Aging"},{"key":"330_CR12","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1159\/000113034","volume":"25","author":"A Kertesz","year":"2008","unstructured":"Kertesz, A. et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement. Geriatr. Cogn. Disord. 25, 178\u2013185 (2008).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"330_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1212\/WNL.57.3.467","volume":"57","author":"I Litvan","year":"2001","unstructured":"Litvan, I. et al. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 57, 467\u2013473 (2001).","journal-title":"Neurology"},{"key":"330_CR14","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.2147\/NDT.S94430","volume":"11","author":"T Kishi","year":"2015","unstructured":"Kishi, T., Matsunaga, S. & Iwata, N. Memantine for the treatment of frontotemporal dementia: a meta-analysis. Neuropsychiatr. Dis. Treat. 11, 2883\u20132885 (2015).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"330_CR15","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3233\/JAD-2010-101632","volume":"23","author":"M Vercelletto","year":"2011","unstructured":"Vercelletto, M. et al. Memantine in behavioral variant frontotemporal dementia: negative results. J. Alzheimer Dis. 23, 749\u2013759 (2011).","journal-title":"J. Alzheimer Dis."},{"key":"330_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1474-4422(12)70320-4","volume":"12","author":"AL Boxer","year":"2013","unstructured":"Boxer, A. L. et al. Memantine in patients with frontotemporal lobar degeneration: a multicenter, randomized, double-blind, placebo-controlled trial. Lancet Neurol. 12, 149\u2013156 (2013).","journal-title":"Lancet Neurol."},{"key":"330_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/01.JGP.0000231744.69631.33","volume":"15","author":"MF Mendez","year":"2007","unstructured":"Mendez, M. F. et al. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am. J. Geriatr. Psychiatr. 15, 84\u201387 (2007).","journal-title":"Am. J. Geriatr. Psychiatr."},{"key":"330_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1034\/j.1600-0404.2001.103002123.x","volume":"103","author":"G Fabbrini","year":"2001","unstructured":"Fabbrini, G. et al. Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol. Scand. 103, 123\u2013125 (2001).","journal-title":"Acta Neurol. Scand."},{"key":"330_CR19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jalz.2009.04.1231","volume":"6","author":"I Liepelt","year":"2010","unstructured":"Liepelt, I. et al. Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: clinical observations as a basis for power calculations and safety analysis. Alzheimers Dement. 6, 70\u201374 (2010).","journal-title":"Alzheimers Dement."},{"key":"330_CR20","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1080\/14656566.2018.1471136","volume":"19","author":"M Lozupone","year":"2018","unstructured":"Lozupone, M. et al. Pharmacotherapy for the treatment of depression in patients with Alzheimer\u2019s disease: a treatment-resistant depressive disorder. Expert Opin. Pharmacother. 19, 823\u2013842 (2018).","journal-title":"Expert Opin. Pharmacother."},{"key":"330_CR21","doi-asserted-by":"publisher","first-page":"212","DOI":"10.4088\/JCP.v58n0506","volume":"58","author":"JR Swartz","year":"1997","unstructured":"Swartz, J. R. et al. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J. Clin. Psychiatry 58, 212\u2013216 (1997).","journal-title":"J. Clin. Psychiatry"},{"key":"330_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/153331750201700504","volume":"17","author":"TW Chow","year":"2002","unstructured":"Chow, T. W. & Mendez, M. F. Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration. Am. J. Alzheimers Dis. Other Demen. 17, 267\u2013272 (2002).","journal-title":"Am. J. Alzheimers Dis. Other Demen."},{"key":"330_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000067021","volume":"49","author":"R Moretti","year":"2003","unstructured":"Moretti, R. et al. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. Eur. Neurol. 49, 13\u201319 (2003).","journal-title":"Eur. Neurol."},{"key":"330_CR24","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s00213-003-1686-5","volume":"172","author":"JB Deakin","year":"2004","unstructured":"Deakin, J. B. et al. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology 172, 400\u2013408 (2004).","journal-title":"Psychopharmacology"},{"key":"330_CR25","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/JGP.0b013e31823033f3","volume":"20","author":"N Herrmann","year":"2012","unstructured":"Herrmann, N. et al. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am. J. Geriatr. Psychiatry 20, 789\u2013797 (2012).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"330_CR26","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1093\/brain\/awv133","volume":"138","author":"LE Hughes","year":"2015","unstructured":"Hughes, L. E. et al. Improving response inhibition systems in frontotemporal dementia with citalopram. Brain 138, 1961\u20131975 (2015).","journal-title":"Brain"},{"key":"330_CR27","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000495561","volume":"11","author":"S Meyer","year":"2019","unstructured":"Meyer, S. et al. Citalopram improves obsessive-compulsive crossword puzzling in frontotemporal dementia. Case Rep. Neurol. 11, 94\u2013105 (2019).","journal-title":"Case Rep. Neurol."},{"key":"330_CR28","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1159\/000077171","volume":"17","author":"F Lebert","year":"2004","unstructured":"Lebert, F. et al. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement. Geriatr. Cogn. Disord. 17, 355\u2013359 (2004).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"330_CR29","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/mds.20465","volume":"20","author":"MF Mendez","year":"2005","unstructured":"Mendez, M. F., Shapira, J. S. & Miller, B. L. Stereotypical movements and frontotemporal dementia. Mov. Disord. 20, 742\u2013745 (2005).","journal-title":"Mov. Disord."},{"key":"330_CR30","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1136\/jnnp.2009.173260","volume":"80","author":"CI Prodan","year":"2009","unstructured":"Prodan, C. I., Monnon, M. & Ross, E. D. Behavioral abnormalities associated with rapid deterioration of language functions in semantic dementia respond to sertraline. J. Neurol. Neurosurg. Psychiatry 80, 1416\u20131417 (2009).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"330_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/17482960601073543","volume":"8","author":"JM Anneser","year":"2007","unstructured":"Anneser, J. M., Jox, R. J. & Borasio, G. D. Inappropriate sexual behavior in a case of ALS and FTD: successful treatment with sertraline. Amyotroph. Lateral Scler. 8, 189\u2013190 (2007).","journal-title":"Amyotroph. Lateral Scler."},{"key":"330_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000076343","volume":"17","author":"M Ikeda","year":"2004","unstructured":"Ikeda, M. et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement. Geriatr. Cogn. Disord. 17, 117\u2013121 (2004).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"330_CR33","first-page":"645","volume":"152","author":"IM Anderson","year":"1995","unstructured":"Anderson, I. M., Scott, K. & Harborne, G. Serotonine and depression in frontal lobe dementia. Am. J. Psychiatry 152, 645 (1995).","journal-title":"Am. J. Psychiatry"},{"key":"330_CR34","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1517\/14656566.2015.1092520","volume":"16","author":"F Panza","year":"2015","unstructured":"Panza, F. et al. Progresses in treating agitation: a major clinical challenge in Alzheimer\u2019s disease. Expert Opin. Pharmacother. 16, 2581\u20132588 (2015).","journal-title":"Expert Opin. Pharmacother."},{"key":"330_CR35","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/gps.774","volume":"18","author":"YA Pijnenburg","year":"2003","unstructured":"Pijnenburg, Y. A. et al. Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. Int. J. Geriatr. Psychiatr. 18, 67\u201372 (2003).","journal-title":"Int. J. Geriatr. Psychiatr."},{"key":"330_CR36","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/00004714-200006000-00018","volume":"20","author":"RC Curtis","year":"2000","unstructured":"Curtis, R. C. & Resch, D. S. Case of Pick\u00b4s central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone. J. Clin. Psychopharmacol. 20, 384\u2013385 (2000).","journal-title":"J. Clin. Psychopharmacol."},{"key":"330_CR37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/15622970601016538","volume":"8","author":"A Fellgiebel","year":"2007","unstructured":"Fellgiebel, A. et al. Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J. Biol. Psychiatry 8, 123\u2013126 (2007).","journal-title":"World J. Biol. Psychiatry"},{"key":"330_CR38","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/153331750301800410","volume":"18","author":"R Moretti","year":"2003","unstructured":"Moretti, R. et al. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer\u2019s disease and other dementias: a 24-month follow-up of 68 patients. Am. J. Alzheimers Dis. Other Demen. 18, 205\u2013214 (2003).","journal-title":"Am. J. Alzheimers Dis. Other Demen."},{"key":"330_CR39","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/JCP.0000000000000414","volume":"35","author":"MK Jha","year":"2015","unstructured":"Jha, M. K. et al. A case of frontotemporal dementia presenting with treatment-refractory psychosis and extreme violence: Response to combination of clozapine, medroxyprogesterone, and sertraline. J. Clin. Psychopharmacol. 35, 732\u2013733 (2015).","journal-title":"J. Clin. Psychopharmacol."},{"key":"330_CR40","first-page":"297","volume":"10","author":"L Riedl","year":"2014","unstructured":"Riedl, L. et al. Frontotemporal lobar degeneration: current perspectives. Neuropsychiatr. Dis. Treat. 10, 297\u2013310 (2014).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"330_CR41","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/ana.20203","volume":"56","author":"JR Hodges","year":"2004","unstructured":"Hodges, J. R. et al. Clinicopathotogical correlates in frontotemporal dementia. Ann. Neurol. 56, 399\u2013406 (2004).","journal-title":"Ann. Neurol."},{"key":"330_CR42","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1001\/jama.279.14.1100","volume":"279","author":"LS Goldman","year":"1998","unstructured":"Goldman, L. S. et al. Diagnosis and treatment of attention-deficit\/hyperactivity disorder in children and adolescents, Council on Scientific Affairs, American Medical Association. JAMA 279, 1100\u20131107 (1998).","journal-title":"JAMA"},{"key":"330_CR43","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.4088\/JCP.v69n1219a","volume":"69","author":"ED Huey","year":"2008","unstructured":"Huey, E. D. et al. Stimulant treatment of frontotemporal dementia in 8 patients. J. Clin. Psychiatry 69, 1981\u20131982 (2008).","journal-title":"J. Clin. Psychiatry"},{"key":"330_CR44","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/sj.npp.1300886","volume":"31","author":"S Rahman","year":"2006","unstructured":"Rahman, S. et al. Methylphenidate (\u2018Ritalin\u2019) can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology 31, 651\u2013658 (2006).","journal-title":"Neuropsychopharmacology"},{"key":"330_CR45","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/ana.20301","volume":"56","author":"DA Reed","year":"2004","unstructured":"Reed, D. A. et al. A clinical trial of bromocriptine for treatment of primary progressive aphasia. Ann. Neurol. 56, 750 (2004).","journal-title":"Ann. Neurol."},{"key":"330_CR46","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/gps.894","volume":"18","author":"G Adler","year":"2003","unstructured":"Adler, G., Teufel, M. & Drach, L. M. Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide. Int. J. Geriatr. Psychiatry 18, 653\u2013655 (2003).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"330_CR47","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/gps.602","volume":"17","author":"R Moretti","year":"2002","unstructured":"Moretti, R. et al. Effects of selegiline on fronto-temporal dementia: a neuropsychological evaluation. Int. J. Geriatr. Psychiatry 17, 391\u2013392 (2002).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"330_CR48","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1093\/brain\/awr171","volume":"134","author":"S Jesso","year":"2011","unstructured":"Jesso, S. et al. The effects of oxytocin on social cognition and behavior in frontotemporal dementia. Brain 134, 2493\u20132501 (2011).","journal-title":"Brain"},{"key":"330_CR49","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1212\/WNL.0000000000001133","volume":"84","author":"EC Finger","year":"2015","unstructured":"Finger, E. C. et al. Oxytocin for frontotemporal dementia: a randomized dose-finding study of safety and tolerability. Neurology 84, 174\u2013181 (2015).","journal-title":"Neurology"},{"key":"330_CR50","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000445873","volume":"16","author":"I Callegari","year":"2016","unstructured":"Callegari, I. et al. Agomelatine improves apathy in frontotemporal dementia. Neurodegener. Dis. 16, 352\u2013356 (2016).","journal-title":"Neurodegener. Dis."},{"key":"330_CR51","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.neubiorev.2018.10.022","volume":"95","author":"V Solfrizzi","year":"2018","unstructured":"Solfrizzi, V. et al. Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: a systematic review. Neurosci. Biobehav. Rev. 95, 480\u2013498 (2018).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"330_CR52","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000369811","volume":"15","author":"M Pardini","year":"2015","unstructured":"Pardini, M. et al. Souvenaid reduces behavioral deficits and improves social cognition skills in frontotemporal dementia: a proof-of-concept study. Neurodegener. Dis. 15, 58\u201362 (2015).","journal-title":"Neurodegener. Dis."},{"key":"330_CR53","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/S1474-4422(17)30408-8","volume":"17","author":"K Augustin","year":"2018","unstructured":"Augustin, K. et al. Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders. Lancet Neurol. 17, 84\u201393 (2018).","journal-title":"Lancet Neurol."},{"key":"330_CR54","doi-asserted-by":"publisher","first-page":"p838","DOI":"10.1016\/j.jalz.2017.07.276","volume":"13","author":"HB Nygaard","year":"2017","unstructured":"Nygaard, H. B. Pharmacokinetics and dynamics of a ketogenic intervention in Alzheimer\u2019s disease and frontotemporal dementia. Alzheimers Dement. 13, p838 (2017).","journal-title":"Alzheimers Dement."},{"key":"330_CR55","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky, K. et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456\u20132477 (2011).","journal-title":"Brain"},{"key":"330_CR56","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jalz.2017.01.011","volume":"13","author":"R Capozzo","year":"2017","unstructured":"Capozzo, R. et al. Clinical and genetic analyses of familial and sporadic frontotemporal dementia patients in Southern Italy. Alzheimers Dement. 13, 858\u2013869 (2017).","journal-title":"Alzheimers Dement."},{"key":"330_CR57","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini, M. L. et al. Classification of primary progressive aphasia and its variants. Neurology 76, 1006\u20131014 (2011).","journal-title":"Neurology"},{"key":"330_CR58","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger, G. U. et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov. Disord. 32, 853\u2013864 (2017).","journal-title":"Mov. Disord."},{"key":"330_CR59","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong, M. J. et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 80, 496\u2013503 (2013).","journal-title":"Neurology"},{"key":"330_CR60","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/21678421.2016.1267768","volume":"18","author":"MJ Strong","year":"2017","unstructured":"Strong, M. J. et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph. Lateral Scler. Frontotemporal Degener. 18, 153\u2013174 (2017).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"330_CR61","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ana.21426","volume":"64","author":"KA Josephs","year":"2008","unstructured":"Josephs, K. A. Frontotemporal dementia and related disorders: deciphering the enigma. Ann. Neurol. 64, 4\u201314 (2008).","journal-title":"Ann. Neurol."},{"key":"330_CR62","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00401-011-0839-6","volume":"122","author":"KA Josephs","year":"2011","unstructured":"Josephs, K. A. et al. Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol. 122, 137\u2013153 (2011).","journal-title":"Acta Neuropathol."},{"key":"330_CR63","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/31508","volume":"393","author":"M Hutton","year":"1998","unstructured":"Hutton, M. et al. Association of missense and 5\u2019-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702\u2013705 (1998).","journal-title":"Nature"},{"key":"330_CR64","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1126\/science.1134108","volume":"314","author":"M Neumann","year":"2006","unstructured":"Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130\u2013133 (2006).","journal-title":"Science"},{"key":"330_CR65","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1093\/brain\/awp214","volume":"132","author":"M Neumann","year":"2009","unstructured":"Neumann, M. et al. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132, 2922\u20132931 (2009).","journal-title":"Brain"},{"key":"330_CR66","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1126\/science.1166066","volume":"323","author":"TJ Kwiatkowski Jr.","year":"2009","unstructured":"Kwiatkowski, T. J. Jr. et al. Mutations in the FUS\/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205\u20131208 (2009).","journal-title":"Science"},{"key":"330_CR67","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1126\/science.1165942","volume":"323","author":"C Vance","year":"2009","unstructured":"Vance, C. et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208\u20131211 (2009).","journal-title":"Science"},{"key":"330_CR68","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1093\/brain\/awr201","volume":"134","author":"M Neumann","year":"2011","unstructured":"Neumann, M. et al. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain 134, 2595\u20132609 (2011).","journal-title":"Brain"},{"key":"330_CR69","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00401-011-0863-6","volume":"122","author":"J Brelstaff","year":"2011","unstructured":"Brelstaff, J. et al. Transportin1: a marker of FTLD-FUS. Acta Neuropathol. 122, 591\u2013600 (2011).","journal-title":"Acta Neuropathol."},{"key":"330_CR70","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrneurol.2017.96","volume":"13","author":"FM Elahi","year":"2017","unstructured":"Elahi, F. M. & Miller, B. L. A clinicopathological approach to the diagnosis of dementia. Nat. Rev. Neurol. 13, 457\u2013476 (2017).","journal-title":"Nat. Rev. Neurol."},{"key":"330_CR71","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1093\/brain\/awr198","volume":"134","author":"JD Rohrer","year":"2011","unstructured":"Rohrer, J. D. et al. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain 134, 2565\u20132581 (2011).","journal-title":"Brain"},{"key":"330_CR72","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1474-4422(13)70090-5","volume":"12","author":"MG Spillantini","year":"2013","unstructured":"Spillantini, M. G. & Goedert, M. Tau pathology and neurodegeneration. Lancet Neurol. 12, 609\u2013622 (2013).","journal-title":"Lancet Neurol."},{"key":"330_CR73","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1093\/brain\/awx254","volume":"140","author":"DC Perry","year":"2017","unstructured":"Perry, D. C. et al. Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain 140, 3329\u20133345 (2017).","journal-title":"Brain"},{"key":"330_CR74","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0014-5793(98)00910-7","volume":"433","author":"C Mailliot","year":"1998","unstructured":"Mailliot, C. et al. Phosphorylation of specific sets of tau isoforms explains different neurodegeneration processes. FEBS Lett. 433, 201\u2013204 (1998).","journal-title":"FEBS Lett."},{"key":"330_CR75","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1046\/j.1471-4159.1999.0721243.x","volume":"72","author":"N Sergeant","year":"1999","unstructured":"Sergeant, N., Wattez, A. & Delacourte, A. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively \u201cexon 10\u201d isoforms. J. Neurochem. 72, 1243\u20131249 (1999).","journal-title":"J. Neurochem."},{"key":"330_CR76","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S0014-5793(97)00859-4","volume":"412","author":"N Sergeant","year":"1997","unstructured":"Sergeant, N. et al. Different distribution of phosphorylated tau protein isoforms in Alzheimer\u2019s and Pick\u2019s diseases. FEBS Lett. 412, 578\u2013582 (1997).","journal-title":"FEBS Lett."},{"key":"330_CR77","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/jnen\/61.6.547","volume":"61","author":"T Togo","year":"2002","unstructured":"Togo, T. et al. Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J. Neuropathol. Exp. Neurol. 61, 547\u2013556 (2002).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"330_CR78","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/jnen\/60.4.328","volume":"60","author":"EH Bigio","year":"2001","unstructured":"Bigio, E. H. et al. Frontal lobe dementia with novel tauopathy: sporadic multiple system tauopathy with dementia. J. Neuropathol. Exp. Neurol. 60, 328\u2013341 (2001).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"330_CR79","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.bbadis.2004.08.007","volume":"1739","author":"M Goedert","year":"2005","unstructured":"Goedert, M. & Jakes, R. Mutations causing neurodegenerative tauopathies. Biochim. Biophys. Acta 1739, 240\u2013250 (2005).","journal-title":"Biochim. Biophys. Acta"},{"key":"330_CR80","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00401-011-0857-4","volume":"122","author":"Z Ahmed","year":"2011","unstructured":"Ahmed, Z. et al. Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies. Acta Neuropathol. 122, 415\u2013428 (2011).","journal-title":"Acta Neuropathol."},{"key":"330_CR81","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00401-014-1380-1","volume":"129","author":"DJ Irwin","year":"2015","unstructured":"Irwin, D. J. et al. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol. 129, 469\u2013491 (2015).","journal-title":"Acta Neuropathol."},{"key":"330_CR82","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/nan.12526","volume":"45","author":"M Neumann","year":"2019","unstructured":"Neumann, M. & Mackenzie, I. R. Review: neuropathology of non-tau frontotemporal lobar degeneration. Neuropathol. Appl. Neurobiol. 45, 19\u201340 (2019).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"330_CR83","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.bbrc.2006.10.093","volume":"351","author":"T Arai","year":"2006","unstructured":"Arai, T. et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 351, 602\u2013611 (2006).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"330_CR84","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00401-011-0845-8","volume":"122","author":"IR Mackenzie","year":"2011","unstructured":"Mackenzie, I. R. et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 122, 111\u2013113 (2011).","journal-title":"Acta Neuropathol."},{"key":"330_CR85","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00401-017-1716-8","volume":"134","author":"IR Mackenzie","year":"2017","unstructured":"Mackenzie, I. R. & Neumann, M. Reappraisal of TDP-43 pathology in FTLD-U subtypes. Acta Neuropathol. 134, 79\u201396 (2017).","journal-title":"Acta Neuropathol."},{"key":"330_CR86","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1212\/WNL.0b013e3182684634","volume":"79","author":"C Dobson-Stone","year":"2012","unstructured":"Dobson-Stone, C. et al. C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts. Neurology 79, 995\u20131001 (2012).","journal-title":"Neurology"},{"key":"330_CR87","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1126\/science.1199214","volume":"332","author":"W Tang","year":"2001","unstructured":"Tang, W. et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 332, 478\u2013484 (2001).","journal-title":"Science"},{"key":"330_CR88","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1083\/jcb.200712039","volume":"181","author":"P Van Damme","year":"2008","unstructured":"Van Damme, P. et al. Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J. Cell Biol. 181, 37\u201341 (2008).","journal-title":"J. Cell Biol."},{"key":"330_CR89","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/nen.0b013e31803020b9","volume":"66","author":"M Neumann","year":"2007","unstructured":"Neumann, M. et al. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J. Neuropathol. Exp. Neurol. 66, 152\u2013157 (2007).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"330_CR90","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","volume":"72","author":"M DeJesus-Hernandez","year":"2011","unstructured":"DeJesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9orf72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245\u2013256 (2011).","journal-title":"Neuron"},{"key":"330_CR91","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.neuron.2013.02.004","volume":"77","author":"PE Ash","year":"2013","unstructured":"Ash, P. E. et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD\/ALS. Neuron 77, 639\u2013646 (2013).","journal-title":"Neuron"},{"key":"330_CR92","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00401-013-1192-8","volume":"126","author":"TF Gendron","year":"2013","unstructured":"Gendron, T. F. et al. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD\/ALS. Acta Neuropathol. 126, 829\u2013844 (2013).","journal-title":"Acta Neuropathol."},{"key":"330_CR93","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00401-013-1189-3","volume":"126","author":"K Mori","year":"2013","unstructured":"Mori, K. et al. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol. 126, 881\u2013893 (2013).","journal-title":"Acta Neuropathol."},{"key":"330_CR94","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1126\/science.1232927","volume":"339","author":"K Mori","year":"2013","unstructured":"Mori, K. et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD\/ALS. Science 339, 1335\u20131338 (2013).","journal-title":"Science"},{"key":"330_CR95","doi-asserted-by":"publisher","first-page":"E4968","DOI":"10.1073\/pnas.1315438110","volume":"110","author":"T Zu","year":"2013","unstructured":"Zu, T. et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc. Natl Acad. Sci. USA 110, E4968\u2013E4977 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"330_CR96","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/2051-5960-2-70","volume":"2","author":"YS Davidson","year":"2014","unstructured":"Davidson, Y. S. et al. Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol. Commun. 2, 70 (2014).","journal-title":"Acta Neuropathol. Commun."},{"key":"330_CR97","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00401-015-1476-2","volume":"130","author":"IR Mackenzie","year":"2015","unstructured":"Mackenzie, I. R. et al. Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers. Acta Neuropathol. 130, 845\u2013861 (2015).","journal-title":"Acta Neuropathol."},{"key":"330_CR98","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00401-012-1020-6","volume":"124","author":"M Neumann","year":"2012","unstructured":"Neumann, M. et al. Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations. Acta Neuropathol. 124, 705\u2013716 (2012).","journal-title":"Acta Neuropathol."},{"key":"330_CR99","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1093\/brain\/awn061","volume":"131","author":"IR Mackenzie","year":"2008","unstructured":"Mackenzie, I. R. et al. Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions. Brain 131, 1282\u20131293 (2008).","journal-title":"Brain"},{"key":"330_CR100","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1212\/01.WNL.0000139809.16817.DD","volume":"63","author":"NJ Cairns","year":"2004","unstructured":"Cairns, N. J. et al. Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology 63, 1376\u20131384 (2004).","journal-title":"Neurology"},{"key":"330_CR101","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s00401-009-0598-9","volume":"118","author":"DG Munoz","year":"2009","unstructured":"Munoz, D. G. et al. FUS pathology in basophilic inclusion body disease. Acta Neuropathol. 118, 617\u2013627 (2009).","journal-title":"Acta Neuropathol."},{"key":"330_CR102","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/BF00307636","volume":"80","author":"H Kusaka","year":"1990","unstructured":"Kusaka, H., Matsumoto, S. & Imai, T. An adult-onset case of sporadic motor neuron disease with basophilic inclusions. Acta Neuropathol. 80, 660\u2013665 (1990).","journal-title":"Acta Neuropathol."},{"key":"330_CR103","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40478-016-0304-9","volume":"4","author":"I Kawakami","year":"2016","unstructured":"Kawakami, I. et al. Chorea as a clinical feature of the basophilic inclusion body disease subtype of fused-in-sarcoma associated frontotemporal lobar degeneration. Acta Neuropathol. Commun. 4, 36 (2016).","journal-title":"Acta Neuropathol. Commun."},{"key":"330_CR104","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00401-010-0698-6","volume":"120","author":"H Urwin","year":"2010","unstructured":"Urwin, H. et al. FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol. 120, 33\u201341 (2010).","journal-title":"Acta Neuropathol."},{"key":"330_CR105","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/ng1609","volume":"37","author":"G Skibinski","year":"2005","unstructured":"Skibinski, G. et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat. Genet. 37, 806\u2013808 (2005).","journal-title":"Nat. Genet."},{"key":"330_CR106","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/hmg\/ddm309","volume":"17","author":"J van der Zee","year":"2008","unstructured":"van der Zee, J. et al. CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro. Hum. Mol. Genet. 17, 313\u2013322 (2008).","journal-title":"Hum. Mol. Genet."},{"key":"330_CR107","doi-asserted-by":"publisher","first-page":"246","DOI":"10.2174\/156720511795563764","volume":"8","author":"AM Isaacs","year":"2011","unstructured":"Isaacs, A. M. et al. Frontotemporal dementia caused by CHMP2B mutations. Curr. Alzheimer Res. 8, 246\u2013251 (2011).","journal-title":"Curr. Alzheimer Res."},{"key":"330_CR108","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1212\/WNL.40.2.251","volume":"40","author":"DS Knopman","year":"1990","unstructured":"Knopman, D. S. et al. Dementia lacking distinctive histologic features: a common non- Alzheimer degenerative dementia. Neurology 40, 251\u2013256 (1990).","journal-title":"Neurology"},{"key":"330_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-009-0612-2","volume":"119","author":"IR Mackenzie","year":"2010","unstructured":"Mackenzie, I. R. et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 119, 1\u20134 (2010).","journal-title":"Acta Neuropathol."},{"key":"330_CR110","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1212\/01.wnl.0000187068.92184.63","volume":"65","author":"JS Goldman","year":"2005","unstructured":"Goldman, J. S. et al. Comparison of family histories in FTLD subtypes and related tauopathies. Neurology 65, 1817\u20131819 (2005).","journal-title":"Neurology"},{"key":"330_CR111","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1212\/WNL.0b013e3181bf997a","volume":"73","author":"JD Rohrer","year":"2009","unstructured":"Rohrer, J. D. et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology 73, 1451\u20131456 (2009).","journal-title":"Neurology"},{"key":"330_CR112","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jamaneurol.2013.3956","volume":"70","author":"EM Wood","year":"2013","unstructured":"Wood, E. M. et al. Development and validation of pedigree classification criteria for frontotemporal lobar degeneration. JAMA Neurol. 70, 1411\u20131417 (2013).","journal-title":"JAMA Neurol."},{"key":"330_CR113","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1007\/s00415-019-09363-4","volume":"266","author":"CV Greaves","year":"2019","unstructured":"Greaves, C. V. & Rohrer, J. D. An update on genetic frontotemporal dementia. J. Neurol. 266, 2075\u20132086 (2019).","journal-title":"J. Neurol."},{"key":"330_CR114","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1093\/brain\/awl271","volume":"129","author":"IR Mackenzie","year":"2006","unstructured":"Mackenzie, I. R. et al. The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain 129, 3081\u20133090 (2006).","journal-title":"Brain"},{"key":"330_CR115","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1093\/brain\/awl276","volume":"129","author":"M Masellis","year":"2006","unstructured":"Masellis, M. et al. Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome. Brain 129, 3115\u20133123 (2006).","journal-title":"Brain"},{"key":"330_CR116","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1212\/WNL.0b013e3181bd82a7","volume":"73","author":"F Moreno","year":"2009","unstructured":"Moreno, F. et al. \u201cFrontotemporoparietal\u201d dementia: clinical phenotype associated with the c.709\u20131G>A PGRN mutation. Neurology 73, 1367\u20131374 (2009).","journal-title":"Neurology"},{"key":"330_CR117","unstructured":"Ghetti, B., Hutton, M. & Wszolek, Z. Neurodegeneration: the molecular pathology of dementia and movement disorders (ed. Dickson, D.) 86\u2013102 (ISN Neuropath Press, 2003)."},{"key":"330_CR118","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/brain\/awf069","volume":"125","author":"SM Pickering-Brown","year":"2002","unstructured":"Pickering-Brown, S. M. et al. Inherited frontotemporal dementia in nine British families associated with intronic mutations in the tau gene. Brain 125, 732\u2013751 (2002).","journal-title":"Brain"},{"key":"330_CR119","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/ng1332","volume":"36","author":"GD Watts","year":"2004","unstructured":"Watts, G. D. et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat. Genet. 36, 377\u2013381 (2004).","journal-title":"Nat. Genet."},{"key":"330_CR120","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/ana.21612","volume":"65","author":"L Benajiba","year":"2009","unstructured":"Benajiba, L. et al. TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann. Neurol. 65, 470\u2013473 (2009).","journal-title":"Ann. Neurol."},{"key":"330_CR121","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1212\/WNL.0b013e3181f07e0c","volume":"75","author":"J Yan","year":"2010","unstructured":"Yan, J. et al. Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS\/dementia. Neurology 75, 807\u2013814 (2010).","journal-title":"Neurology"},{"key":"330_CR122","doi-asserted-by":"publisher","first-page":"2949.e13-7","DOI":"10.1016\/j.neurobiolaging.2012.07.002","volume":"33","author":"M Synofzik","year":"2012","unstructured":"Synofzik, M. et al. Screening in ALS and FTD patients reveals 3 novel UBQLN2 mutations outside the PXX domain and a pure FTD phenotype. Neurobiol. Aging 33, 2949.e13-7 (2012).","journal-title":"Neurobiol. Aging"},{"key":"330_CR123","first-page":"1403","volume":"70","author":"I Le Ber","year":"2013","unstructured":"Le Ber, I. et al. SQSTM1 mutations in French patients with frontotemporal dementia or frontotemporal dementia with amyotrophic lateral sclerosis. JAMA Neurol. 70, 1403\u20131410 (2013).","journal-title":"JAMA Neurol."},{"key":"330_CR124","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1093\/brain\/awu138","volume":"137","author":"S Bannwarth","year":"2014","unstructured":"Bannwarth, S. et al. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain 137, 2329\u20132345 (2014).","journal-title":"Brain"},{"key":"330_CR125","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00401-015-1436-x","volume":"130","author":"C Pottier","year":"2015","unstructured":"Pottier, C. et al. Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathol. 130, 77\u201392 (2015).","journal-title":"Acta Neuropathol."},{"key":"330_CR126","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11253","volume":"15","author":"KL Williams","year":"2016","unstructured":"Williams, K. L. et al. CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nat. Commun. 15, 11253 (2016).","journal-title":"Nat. Commun."},{"key":"330_CR127","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.neuron.2017.07.025","volume":"95","author":"IR Mackenzie","year":"2017","unstructured":"Mackenzie, I. R. et al. TIA1 Mutations in amyotrophic lateral sclerosis and frontotemporal dementia promote phase separation and alter stress granule dynamics. Neuron 95, 808\u2013816 (2017).","journal-title":"Neuron"},{"key":"330_CR128","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/humu.22319","volume":"34","author":"S Lattante","year":"2013","unstructured":"Lattante, S., Rouleau, G. A. & Kabashi, E. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. Hum. Mutat. 34, 812\u2013826 (2013).","journal-title":"Hum. Mutat."},{"key":"330_CR129","doi-asserted-by":"publisher","first-page":"266.e1","DOI":"10.1016\/j.neurobiolaging.2018.06.015","volume":"71","author":"M de Majo","year":"2018","unstructured":"de Majo, M. et al. ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function. Neurobiol. Aging 71, 266.e1\u2013266.e10 (2018).","journal-title":"Neurobiol. Aging"},{"key":"330_CR130","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/j.parkreldis.2015.09.020","volume":"22","author":"DJ Irwin","year":"2016","unstructured":"Irwin, D. J. Tauopathies as clinicopathological entities. Parkinsonism Relat. Disord. 22, S29\u2013S33 (2016).","journal-title":"Parkinsonism Relat. Disord."},{"issue":"Suppl. 1","key":"330_CR131","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/jnc.13669","volume":"138","author":"P Oeckl","year":"2016","unstructured":"Oeckl, P., Steinacker, P., Feneberg, E. & Otto, M. Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update. J. Neurochem. 138 (Suppl. 1), 184\u2013192 (2016).","journal-title":"J. Neurochem."},{"key":"330_CR132","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fpsyt.2019.00075","volume":"10","author":"MN Liu","year":"2019","unstructured":"Liu, M. N., Lau, C. I. & Lin, C. P. Precision Medicine for frontotemporal dementia. Front. Psychiatry 10, 75 (2019).","journal-title":"Front. Psychiatry"},{"key":"330_CR133","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3389\/fnins.2019.00548","volume":"13","author":"TJ Hedl","year":"2019","unstructured":"Hedl, T. J. et al. Proteomics approaches for biomarker and drug target discovery in ALS and FTD. Front. Neurosci. 13, 548 (2019).","journal-title":"Front. Neurosci."},{"key":"330_CR134","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr.","year":"2018","unstructured":"Jack, C. R. Jr. et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement."},{"key":"330_CR135","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jalz.2012.03.003","volume":"9","author":"AL Boxer","year":"2013","unstructured":"Boxer, A. L. et al. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement. 9, 189\u2013198 (2013).","journal-title":"Alzheimers Dement."},{"key":"330_CR136","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jns.2014.07.015","volume":"345","author":"W Tang","year":"2014","unstructured":"Tang, W. et al. Assessment of CSF Ab42 as an aid to discriminating Alzheimer\u2019s disease from other dementias and mild cognitive impairment: a meta-analysis of 50 studies. J. Neurol. Sci. 345, 26\u201336 (2014).","journal-title":"J. Neurol. Sci."},{"key":"330_CR137","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1515\/CCLM.2011.086","volume":"49","author":"AC van Harten","year":"2011","unstructured":"van Harten, A. C. et al. Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin. Chem. Lab. Med. 49, 353\u2013366 (2011).","journal-title":"Clin. Chem. Lab. Med."},{"key":"330_CR138","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00702-014-1226-y","volume":"121","author":"W Tang","year":"2014","unstructured":"Tang, W. et al. Does CSF p-tau181 help to discriminate Alzheimer\u2019s disease from other dementias and mild cognitive impairment? A meta-analysis of the literature. J. Neural. Transm. 121, 1541\u20131553 (2014).","journal-title":"J. Neural. Transm."},{"key":"330_CR139","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1093\/brain\/awv181","volume":"138","author":"T Skillb\u00e4ck","year":"2015","unstructured":"Skillb\u00e4ck, T. et al. Cerebrospinal fluid tau and amyloid-\u03b21-42 in patients with dementia. Brain 138, 2716\u20132731 (2015).","journal-title":"Brain"},{"key":"330_CR140","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jns.2015.09.022","volume":"358","author":"I Baldeiras","year":"2015","unstructured":"Baldeiras, I. et al. Cerebrospinal fluid Ab40 is similarly reduced in patients with Frontotemporal lobar degeneration and Alzheimer\u2019s disease. J. Neurol. Sci. 358, 308\u2013316 (2015).","journal-title":"J. Neurol. Sci."},{"key":"330_CR141","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3389\/fneur.2015.00138","volume":"6","author":"H Struyfs","year":"2015","unstructured":"Struyfs, H. et al. Cerebrospinal fluid P-Tau181P: biomarker for improved differential dementia diagnosis. Front. Neurol. 6, 138 (2015).","journal-title":"Front. Neurol."},{"key":"330_CR142","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1136\/jnnp.2006.107326","volume":"78","author":"D de Jong","year":"2007","unstructured":"de Jong, D. et al. CSF neurofilament proteins in the differential diagnosis of dementia. J. Neurol. Neurosurg. Psychiatry 78, 936\u2013938 (2007).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"330_CR143","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.jalz.2017.12.008","volume":"14","author":"I Zerr","year":"2018","unstructured":"Zerr, I. et al. Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimers Dement. 14, 751\u2013763 (2018).","journal-title":"Alzheimers Dement."},{"key":"330_CR144","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fneur.2015.00091","volume":"6","author":"MK Herbert","year":"2015","unstructured":"Herbert, M. K. CSF neurofilament light chain but not FLT3 ligand discriminates Parkinsonian disorders. Front. Neurol. 6, 91 (2015).","journal-title":"Front. Neurol."},{"key":"330_CR145","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1136\/jnnp-2014-309562","volume":"86","author":"NK Magdalinou","year":"2015","unstructured":"Magdalinou, N. K. et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J. Neurol. Neurosurg. Psychiatry 86, 1240\u20131247 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"330_CR146","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1212\/01.wnl.0000436625.63650.27","volume":"81","author":"WT Hu","year":"2013","unstructured":"Hu, W. T. et al. Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP. Neurol. 81, 1945\u20131952 (2013).","journal-title":"Neurol."},{"key":"330_CR147","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3389\/fneur.2018.00504","volume":"9","author":"P Kortvelyessy","year":"2018","unstructured":"Kortvelyessy, P. et al. CSF biomarkers of neurodegeneration in progressive non-fluent aphasia and other forms of frontotemporal dementia: clues for pathomechanisms? Front. Neurol. 9, 504 (2018).","journal-title":"Front. Neurol."},{"key":"330_CR148","doi-asserted-by":"publisher","first-page":"e1231","DOI":"10.1212\/WNL.0000000000005261","volume":"90","author":"LHH Meeter","year":"2018","unstructured":"Meeter, L. H. H. et al. Clinical value of neurofilament and phospho-tau\/tau ratio in the frontotemporal dementia spectrum. Neurology 90, e1231\u2013e1239 (2018).","journal-title":"Neurology"},{"key":"330_CR149","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1136\/jnnp-2017-317260","volume":"89","author":"MS Foiani","year":"2018","unstructured":"Foiani, M. S. et al. Plasma tau is increased in frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry 89, 804\u2013807 (2018).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"330_CR150","doi-asserted-by":"publisher","first-page":"R77","DOI":"10.1093\/hmg\/ddt349","volume":"22","author":"J Janssens","year":"2013","unstructured":"Janssens, J. & Van Broeckhoven, C. Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders. Hum. Mol. Genet. 22, R77\u2013R87 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"330_CR151","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/21678421.2014.971812","volume":"16","author":"B Borroni","year":"2015","unstructured":"Borroni, B. et al. Csf p-tau181\/tau ratio as biomarker for TDP pathology in frontotemporal dementia. Amyotroph. Lateral Scler. Frontotemporal Degener. 16, 86\u201391 (2015).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"330_CR152","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1212\/01.wnl.0000325058.10218.fc","volume":"14","author":"R Ghidoni","year":"2008","unstructured":"Ghidoni, R. et al. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology 14, 1235\u20131239 (2008).","journal-title":"Neurology"},{"key":"330_CR153","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/brain\/awn352","volume":"132","author":"N Finch","year":"2009","unstructured":"Finch, N. et al. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain 132, 583\u2013591 (2009).","journal-title":"Brain"},{"key":"330_CR154","doi-asserted-by":"publisher","first-page":"101711","DOI":"10.1016\/j.nicl.2019.101711","volume":"22","author":"M Bruun","year":"2019","unstructured":"Bruun, M. et al. Detecting frontotemporal dementia syndromes using MRI biomarkers. Neuroimage Clin. 22, 101711 (2019).","journal-title":"Neuroimage Clin."},{"key":"330_CR155","first-page":"204","volume":"6","author":"S D'Alton","year":"2014","unstructured":"D\u2019Alton, S. & Lewis, J. Therapeutic and diagnostic challenges for frontotemporal dementia. Front. Aging Neurosci. 6, 204 (2014).","journal-title":"Front. Aging Neurosci."},{"key":"330_CR156","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/17460441.2017.1329294","volume":"12","author":"L De Conti","year":"2017","unstructured":"De Conti, L., Borroni, B. & Baralle, M. New routes in frontotemporal dementia drug discovery. Expert Opin. Drug Discov. 12, 659\u2013671 (2017).","journal-title":"Expert Opin. Drug Discov."},{"key":"330_CR157","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/14737175.2019.1606715","volume":"19","author":"F Panza","year":"2019","unstructured":"Panza, F. et al. Disease-modifying therapies for tauopathies: agents in the pipeline. Expert Rev. Neurother. 19, 397\u2013408 (2019).","journal-title":"Expert Rev. Neurother."},{"key":"330_CR158","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1091\/mbc.3.10.1141","volume":"3","author":"DN Drechsel","year":"1992","unstructured":"Drechsel, D. N. et al. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol. Biol. Cell 3, 1141\u20131154 (1992).","journal-title":"Mol. Biol. Cell"},{"key":"330_CR159","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/0896-6273(89)90210-9","volume":"3","author":"M Goedert","year":"1989","unstructured":"Goedert, M. et al. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer\u2019s disease. Neuron 3, 519\u2013526 (1989).","journal-title":"Neuron"},{"key":"330_CR160","doi-asserted-by":"publisher","first-page":"10626","DOI":"10.1021\/bi00158a027","volume":"3","author":"A Andreadis","year":"1992","unstructured":"Andreadis, A., Brown, W. M. & Kosik, K. S. Structure and novel exons of the human tau gene. Biochemistry 3, 10626\u201310633 (1992).","journal-title":"Biochemistry"},{"key":"330_CR161","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1046\/j.0014-2956.2001.02649.x","volume":"269","author":"VN Uversky","year":"2002","unstructured":"Uversky, V. N. What does it mean to be natively unfolded? Eur. J. Biochem. 269, 2\u201312 (2002).","journal-title":"Eur. J. Biochem."},{"key":"330_CR162","doi-asserted-by":"publisher","first-page":"10526","DOI":"10.1021\/bi800783d","volume":"47","author":"S Jeganathan","year":"2008","unstructured":"Jeganathan, S. et al. The natively unfolded character of tau and its aggregation to Alzheimer-like paired helical filaments. Biochemistry 47, 10526\u201310539 (2008).","journal-title":"Biochemistry"},{"key":"330_CR163","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1016\/S0021-9258(17)42989-9","volume":"259","author":"G Lindwall","year":"1984","unstructured":"Lindwall, G. & Cole, R. D. Phosphorylation affects the ability of tau protein to promote microtubule assembly. J. Biol. Chem. 259, 5301\u20135305 (1984).","journal-title":"J. Biol. Chem."},{"key":"330_CR164","doi-asserted-by":"publisher","first-page":"19855","DOI":"10.1074\/jbc.R114.549295","volume":"18","author":"BB Holmes","year":"2014","unstructured":"Holmes, B. B. & Diamond, M. I. Prion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic target. J. Biol. Chem. 18, 19855\u201319861 (2014).","journal-title":"J. Biol. Chem."},{"key":"330_CR165","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1097\/WCO.0b013e32834cd442","volume":"24","author":"JD Rohrer","year":"2011","unstructured":"Rohrer, J. D. & Warren, J. D. Phenotypic signatures of genetic frontotemporal dementia. Curr. Opin. Neurol. 24, 542\u2013549 (2011).","journal-title":"Curr. Opin. Neurol."},{"key":"330_CR166","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3233\/JAD-160860","volume":"55","author":"A Papazacharias","year":"2017","unstructured":"Papazacharias, A. et al. Bipolar disorder and frontotemporal dementia: an intriguing association. J. Alzheimers Dis. 55, 973\u2013979 (2017).","journal-title":"J. Alzheimers Dis."},{"key":"330_CR167","doi-asserted-by":"publisher","first-page":"25326","DOI":"10.1074\/jbc.272.40.25326","volume":"272","author":"M Hong","year":"1997","unstructured":"Hong, M. et al. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J. Biol. Chem. 272, 25326\u201325332 (1997).","journal-title":"J. Biol. Chem."},{"key":"330_CR168","doi-asserted-by":"publisher","first-page":"6990","DOI":"10.1073\/pnas.0500466102","volume":"102","author":"W Noble","year":"2005","unstructured":"Noble, W. et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl Acad. Sci. USA 102, 6990\u20136995 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"330_CR169","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1111\/j.1471-4159.2006.04139.x","volume":"99","author":"T Engel","year":"2006","unstructured":"Engel, T. et al. Chronic lithium administration to FTDP-17 tau and GSK-3\u03b2 overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J. Neurochem. 99, 1445\u20131555 (2006).","journal-title":"J. Neurochem."},{"key":"330_CR170","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00703677 (2015)."},{"key":"330_CR171","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/mds.25815","volume":"29","author":"GU H\u00f6glinger","year":"2014","unstructured":"H\u00f6glinger, G. U. et al. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Mov. Disord. 29, 479\u2013487 (2014).","journal-title":"Mov. Disord."},{"key":"330_CR172","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/mds.25824","volume":"29","author":"E Tolosa","year":"2014","unstructured":"Tolosa, E. et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov. Disord. 29, 470\u2013478 (2014).","journal-title":"Mov. Disord."},{"key":"330_CR173","doi-asserted-by":"publisher","first-page":"11213","DOI":"10.1073\/pnas.93.20.11213","volume":"93","author":"CM Wischik","year":"1996","unstructured":"Wischik, C. M. et al. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc. Natl Acad. Sci. USA 93, 11213\u201311218 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"330_CR174","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1586\/14737175.2016.1140039","volume":"16","author":"D Seripa","year":"2016","unstructured":"Seripa, D. et al. Tau-directed approaches for the treatment of Alzheimer\u2019s disease: focus on leuco-methylthioninium. Expert Rev. Neurother. 16, 259\u2013277 (2016).","journal-title":"Expert Rev. Neurother."},{"key":"330_CR175","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","volume":"388","author":"S Gauthier","year":"2016","unstructured":"Gauthier, S. et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 388, 2873\u20132884 (2016).","journal-title":"Lancet"},{"key":"330_CR176","unstructured":"TauRx Pharmaceuticals, Press Release at the 10th International Conference on Frontotemporal Dementias, Munich, August 31\u2013September 2 https:\/\/taurx.com\/trx-237-007-phase-3-clinical-trial-update.pdf (2016)."},{"key":"330_CR177","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/nm.3951","volume":"21","author":"SW Min","year":"2015","unstructured":"Min, S. W. et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat. Med. 21, 1154\u20131162 (2015).","journal-title":"Nat. Med."},{"key":"330_CR178","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02422485 (2018)."},{"key":"330_CR179","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3233\/JAD-140996","volume":"43","author":"K Paholikova","year":"2015","unstructured":"Paholikova, K. et al. N-terminal truncation of microtubule associated protein tau dysregulates its cellular localization. J. Alzheimers Dis. 43, 915\u2013926 (2015).","journal-title":"J. Alzheimers Dis."},{"key":"330_CR180","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/alzrt278","volume":"6","author":"E Kontsekova","year":"2014","unstructured":"Kontsekova, E. et al. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer\u2019s disease model. Alzheimers Res. Ther. 6, 44 (2014).","journal-title":"Alzheimers Res. Ther."},{"key":"330_CR181","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S1474-4422(16)30331-3","volume":"16","author":"P Novak","year":"2017","unstructured":"Novak, P. et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 16, 123\u2013134 (2017).","journal-title":"Lancet Neurol."},{"key":"330_CR182","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1474-4422(16)30340-4","volume":"16","author":"F Panza","year":"2017","unstructured":"Panza, F. & Logroscino, G. Anti-tau vaccine in Alzheimer\u2019s disease: a tentative step. Lancet Neurol. 16, 99\u2013100 (2017).","journal-title":"Lancet Neurol."},{"key":"330_CR183","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13195-018-0436-1","volume":"10","author":"P Novak","year":"2018","unstructured":"Novak, P. et al. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer\u2019s disease. Alzheimers Res. Ther. 10, 108 (2018).","journal-title":"Alzheimers Res. Ther."},{"key":"330_CR184","unstructured":"AXON Neuroscience SE. Axon Announces Positive Results From Phase II ADAMANT Trial for AADvac1 in Alzheimer\u2019s Disease. CISION PR Newswire https:\/\/www.prnewswire.com\/news-releases\/axon-announces-positive-results-from-phase-ii-adamant-trial-for-aadvac1-in-alzheimers-disease-300914509.html (2019)."},{"key":"330_CR185","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03174886 (2019)."},{"key":"330_CR186","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00702-014-1315-y","volume":"122","author":"CL Dai","year":"2015","unstructured":"Dai, C. L. et al. Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies. J. Neural. Transm. 122, 607\u2013617 (2015).","journal-title":"J. Neural. Transm."},{"key":"330_CR187","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2217\/imt-2016-0019","volume":"8","author":"F Panza","year":"2016","unstructured":"Panza, F. et al. Tau-based therapeutics for Alzheimer\u2019s disease: active and passive immunotherapy. Immunotherapy 8, 1119\u20131134 (2016).","journal-title":"Immunotherapy"},{"key":"330_CR188","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.neurobiolaging.2014.09.007","volume":"36","author":"J Bright","year":"2015","unstructured":"Bright, J. et al. Human secreted tau increases amyloid-\u03b2 production. Neurobiol. Aging 36, 693\u2013709 (2015).","journal-title":"Neurobiol. Aging"},{"key":"330_CR189","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02294851 (2017)."},{"key":"330_CR190","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02460094 (2018)."},{"key":"330_CR191","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1474-4422(19)30139-5","volume":"18","author":"AL Boxer","year":"2019","unstructured":"Boxer, A. L. et al. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 18, 549\u2013558 (2019).","journal-title":"Lancet Neurol."},{"key":"330_CR192","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03068468 (2019)."},{"key":"330_CR193","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03658135 (2019)."},{"key":"330_CR194","unstructured":"Gosuranemab, Biogen\u2019s Anti-Tau Immunotherapy, Does not fly for PSP. ALZFORUM https:\/\/www.alzforum.org\/news\/research-news\/gosuranemab-biogens-anti-tau-immunotherapy-does-not-fly-psp (2019)."},{"key":"330_CR195","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00401-011-0825-z","volume":"121","author":"H Braak","year":"2011","unstructured":"Braak, H. & Del Tredici, K. Alzheimer\u2019s pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathol. 121, 589\u2013595 (2011).","journal-title":"Acta Neuropathol."},{"key":"330_CR196","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02494024 (2017)."},{"key":"330_CR197","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03413319 (2019)."},{"key":"330_CR198","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02985879 (2020)."},{"key":"330_CR199","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03391765 (2019)."},{"key":"330_CR200","unstructured":"Carroll, J. AbbVie scraps an anti-tau study, and that may foretell more big trouble for a beleaguered Biogen. ENDPOINTS NEWS. https:\/\/endpts.com\/abbvie-scraps-an-anti-tau-study-and-that-may-foretell-more-big-trouble-for-a-beleaguered-biogen\/ (2019)."},{"key":"330_CR201","unstructured":"To Block Tau\u2019s Proteopathic Spread, Antibody Must Attack its Mid-Region. ALZFORUM. https:\/\/www.alzforum.org\/news\/conference-coverage\/block-taus-proteopathic-spread-antibody-must-attack-its-mid-region (2018)."},{"key":"330_CR202","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03464227 (2018)."},{"key":"330_CR203","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04185415 (2020)."},{"key":"330_CR204","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/npp.2013.23","volume":"38","author":"LF Jarskog","year":"2013","unstructured":"Jarskog, L. F. et al. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology 38, 1245\u20131252 (2013).","journal-title":"Neuropsychopharmacology"},{"key":"330_CR205","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.schres.2011.11.001","volume":"136","author":"DC Javitt","year":"2012","unstructured":"Javitt, D. C. et al. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr. Res. 136, 25\u201331 (2012).","journal-title":"Schizophr. Res."},{"key":"330_CR206","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1124\/jpet.107.129551","volume":"323","author":"I Vulih-Shultzman","year":"2007","unstructured":"Vulih-Shultzman, I. et al. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J. Pharmacol. Exp. Ther. 323, 438\u2013449 (2007).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"330_CR207","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1124\/jpet.107.130526","volume":"325","author":"Y Matsuoka","year":"2008","unstructured":"Matsuoka, Y. et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer\u2019s disease. J. Pharmacol. Exp. Ther. 325, 146\u2013153 (2008).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"330_CR208","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.nbd.2013.04.012","volume":"56","author":"Y Jouroukhin","year":"2013","unstructured":"Jouroukhin, Y. et al. NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport. Neurobiol. Dis. 56, 79\u201394 (2013).","journal-title":"Neurobiol. Dis."},{"key":"330_CR209","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000348347","volume":"35","author":"BH Morimoto","year":"2013","unstructured":"Morimoto, B. H. et al. A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 35, 325\u2013326 (2013).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"330_CR210","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","volume":"13","author":"AL Boxer","year":"2014","unstructured":"Boxer, A. L. et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2\/3 trial. Lancet Neurol. 13, 676\u2013685 (2014).","journal-title":"Lancet Neurol."},{"key":"330_CR211","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01056965 (2019)."},{"key":"330_CR212","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1001\/jamaneurol.2019.3812","volume":"77","author":"RM Tsai","year":"2020","unstructured":"Tsai, R. M. et al. Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with Alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome: a randomized clinical trial. JAMA Neurol. 77, 215\u2013224 (2020).","journal-title":"JAMA Neurol."},{"key":"330_CR213","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.30","volume":"3","author":"R Sud","year":"2014","unstructured":"Sud, R., Geller, E. T. & Schellenberg, G. D. Antisense-mediated exon skipping decreases tau protein expression: a potential therapy for tauopathies. Mol. Ther. Nucleic Acids 3, e180 (2014).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"330_CR214","doi-asserted-by":"publisher","first-page":"42986","DOI":"10.1074\/jbc.M105113200","volume":"276","author":"B Kalbfuss","year":"2001","unstructured":"Kalbfuss, B., Mabon, S. A. & Misteli, T. Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17. J. Biol. Chem. 276, 42986\u201342993 (2001).","journal-title":"J. Biol. Chem."},{"key":"330_CR215","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag0481","volume":"9","author":"SL DeVos","year":"2017","unstructured":"DeVos, S. L. et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci. Transl. Med. 9, eaag0481 (2017).","journal-title":"Sci. Transl. Med."},{"key":"330_CR216","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03186989 (2020)."},{"key":"330_CR217","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1042\/BST20120071","volume":"40","author":"Y Wang","year":"2012","unstructured":"Wang, Y. & Mandelkow, E. Degradation of tau protein by autophagy and proteasomal pathways. Biochem. Soc. Trans. 40, 644\u2013652 (2012).","journal-title":"Biochem. Soc. Trans."},{"key":"330_CR218","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.jalz.2016.06.006","volume":"12","author":"MR Khanna","year":"2016","unstructured":"Khanna, M. R. et al. Therapeutic strategies for the treatment of tauopathies: hopes and challenges. Alzheimers Dement. 12, 1051\u20131065 (2016).","journal-title":"Alzheimers Dement."},{"key":"330_CR219","doi-asserted-by":"publisher","first-page":"9511","DOI":"10.1073\/pnas.0701055104","volume":"104","author":"W Luo","year":"2007","unstructured":"Luo, W. et al. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc. Natl Acad. Sci. USA 104, 9511\u20139516 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"330_CR220","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.cell.2014.01.037","volume":"156","author":"GE Karagoz","year":"2014","unstructured":"Karagoz, G. E. et al. Hsp90-Tau complex reveals molecular basis for specificity in chaperone action. Cell 156, 963\u2013974 (2014).","journal-title":"Cell"},{"key":"330_CR221","doi-asserted-by":"publisher","first-page":"366","DOI":"10.2174\/138161213804143617","volume":"19","author":"S Soga","year":"2013","unstructured":"Soga, S., Akinaga, S. & Shiotsu, Y. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development. Curr. Pharm. Des. 19, 366\u2013376 (2013).","journal-title":"Curr. Pharm. Des."},{"key":"330_CR222","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1096\/fj.05-5343fje","volume":"20","author":"CA Dickey","year":"2006","unstructured":"Dickey, C. A. et al. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser\/Thr sites but not KXGS (MARK) sites. FASEB J. 20, 753\u2013755 (2006).","journal-title":"FASEB J."},{"key":"330_CR223","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.molmed.2004.04.006","volume":"10","author":"A Kamal","year":"2004","unstructured":"Kamal, A., Boehm, M. F. & Burrows, F. J. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol. Med. 10, 283\u2013290 (2004).","journal-title":"Trends Mol. Med."},{"key":"330_CR224","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1126\/science.292.5521.1552","volume":"292","author":"NF Bence","year":"2001","unstructured":"Bence, N. F., Sampat, R. M. & Kopito, R. R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552\u20131555 (2001).","journal-title":"Science"},{"key":"330_CR225","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062459","volume":"8","author":"S Ozcelik","year":"2013","unstructured":"Ozcelik, S. et al. Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice. PLoS One 8, e62459 (2013).","journal-title":"PLoS One"},{"key":"330_CR226","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142340","volume":"10","author":"R Siman","year":"2015","unstructured":"Siman, R., Cocca, R. & Dong, Y. The mTOR inhibitor rapamycin mitigates perforant pathway neurodegeneration and synapse loss in a mouse model of early-stage Alzheimer-type tauopathy. PLoS One 10, e0142340 (2015).","journal-title":"PLoS One"},{"key":"330_CR227","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.tips.2017.03.011","volume":"38","author":"ME Orr","year":"2017","unstructured":"Orr, M. E., Sullivan, A. C. & Frost, B. A brief overview of tauopathy: causes, consequences, and therapeutic strategies. Trends Pharmacol. Sci. 38, 637\u2013648 (2017).","journal-title":"Trends Pharmacol. Sci."},{"key":"330_CR228","doi-asserted-by":"publisher","first-page":"10804","DOI":"10.1073\/pnas.0400348101","volume":"101","author":"F Liu","year":"2004","unstructured":"Liu, F. et al. O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer\u2019s disease. Proc. Natl Acad. Sci. USA 101, 10804\u201310809 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"330_CR229","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1093\/brain\/awp099","volume":"132","author":"F Liu","year":"2009","unstructured":"Liu, F. et al. Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer\u2019s disease. Brain 132, 1820\u20131832 (2009).","journal-title":"Brain"},{"key":"330_CR230","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084442","volume":"8","author":"P Borghgraef","year":"2013","unstructured":"Borghgraef, P. et al. Increasing brain protein O-GlcNAc-ylation mitigates breathing defects and mortality of Tau.P301L mice. PLoS One 8, e84442 (2013).","journal-title":"PLoS One"},{"key":"330_CR231","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13024-017-0181-0","volume":"12","author":"NB Hastings","year":"2017","unstructured":"Hastings, N. B. et al. Inhibition of O-GlcNAcase leads to elevation of OGlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice. Mol. Neurodegener. 12, 39 (2017).","journal-title":"Mol. Neurodegener."},{"key":"330_CR232","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt214","volume":"5","author":"AM Pooler","year":"2013","unstructured":"Pooler, A. M. et al. Propagation of tau pathology in Alzheimer\u2019s disease: identification of novel therapeutic targets. Alzheimers Res. Ther. 5, 1\u20138 (2013).","journal-title":"Alzheimers Res. Ther."},{"key":"330_CR233","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06117-y","volume":"7","author":"B Borroni","year":"2017","unstructured":"Borroni, B. et al. Anti-AMPA GluA3 antibodies in frontotemporal dementia: a new molecular target. Sci. Rep. 7, 6723 (2017).","journal-title":"Sci. Rep."},{"key":"330_CR234","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2174\/1567205015666180119104825","volume":"15","author":"A Alberici","year":"2018","unstructured":"Alberici, A. et al. Autoimmunity and frontotemporal dementia. Curr. Alzheimer Res. 15, 602\u2013609 (2018).","journal-title":"Curr. Alzheimer Res."},{"key":"330_CR235","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3389\/fnins.2019.00304","volume":"13","author":"A Benussi","year":"2019","unstructured":"Benussi, A. et al. Toward a glutamate hypothesis of frontotemporal dementia. Front. Neurosci. 13, 304 (2019).","journal-title":"Front. Neurosci."},{"key":"330_CR236","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021023","volume":"6","author":"Y Zheng","year":"2011","unstructured":"Zheng, Y. et al. C-terminus of progranulin interacts with the beta-propeller region of sortilin to regulate progranulin trafficking. PLoS One 6, e21023 (2011).","journal-title":"PLoS One"},{"key":"330_CR237","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.celrep.2013.06.007","volume":"4","author":"T Nonaka","year":"2013","unstructured":"Nonaka, T. et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep. 4, 124\u2013134 (2013).","journal-title":"Cell Rep."},{"key":"330_CR238","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00401-010-0659-0","volume":"119","author":"BC Kraemer","year":"2010","unstructured":"Kraemer, B. C. et al. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol. 119, 409\u2013419 (2010).","journal-title":"Acta Neuropathol."},{"key":"330_CR239","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1016\/j.febslet.2009.06.042","volume":"583","author":"M Yamashita","year":"2009","unstructured":"Yamashita, M. et al. Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS Lett. 583, 2419\u20132424 (2009).","journal-title":"FEBS Lett."},{"key":"330_CR240","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/1087057113501553","volume":"19","author":"JD Boyd","year":"2014","unstructured":"Boyd, J. D. et al. A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity. J. Biomol. Screen. 19, 44\u201356 (2014).","journal-title":"J. Biomol. Screen."},{"key":"330_CR241","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1523\/JNEUROSCI.5757-10.2011","volume":"31","author":"A Capell","year":"2011","unstructured":"Capell, A. et al. Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase. J. Neurosci. 31, 1885\u20131894 (2011).","journal-title":"J. Neurosci."},{"key":"330_CR242","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s10072-014-1683-y","volume":"35","author":"A Alberici","year":"2014","unstructured":"Alberici, A. et al. Results from a pilot study on amiodarone administration in monogenic frontotemporal dementia with granulin mutation. Neurol. Sci. 35, 1215\u20131219 (2014).","journal-title":"Neurol. Sci."},{"key":"330_CR243","doi-asserted-by":"publisher","first-page":"16101","DOI":"10.1074\/jbc.M110.193433","volume":"286","author":"B Cenik","year":"2011","unstructured":"Cenik, B. et al. Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. J. Biol. Chem. 286, 16101\u201316108 (2011).","journal-title":"J. Biol. Chem."},{"key":"330_CR244","unstructured":"Patzke, H. et al. Development of the novel histone deacetylase inhibitor EVP-0334 for CNS indications [Poster 831.21\/I12]. 38th Annual Meeting for the Society of Neuroscience https:\/\/www.abstractsonline.com\/plan\/ViewAbstract.aspx?mID=1981&sKey=7608b1d6-24c8-4a0d-85e8-68357f77ef82&cKey=b58f0420-5bde-407b-afe3-948d274e708b&mKey=afea068d-d012-4520-8e42-10e4d1af7944 (2008)."},{"key":"330_CR245","unstructured":"Leventhal, L. et al. The histone deacetylase inhibitor EVP-0334 is pro-cognitive in mice [Poster 831.20\/I11]. 38th Annual Meeting for the Society of Neuroscience https:\/\/www.abstractsonline.com\/plan\/ViewAbstract.aspx?mID=1981&sKey=7608b1d6-24c8-4a0d-85e8-68357f77ef82&cKey=4256d6f9-3c58-4903-83ed-8d46d22972dd&mKey=afea068d-d012-4520-8e42-10e4d1af7944 (2008)."},{"key":"330_CR246","unstructured":"Patzke, H. et al. The novel histone deacetylase inhibitor EVP-0334 is pro-cognitive in rats [Poster 886.4\/FF106]. 39th Annual Meeting for the Society of Neuroscience https:\/\/www.abstractsonline.com\/Plan\/ViewAbstract.aspx?sKey=74e6ee34-69bf-41db-a73b-fdf5d47df43e&cKey=cfc48c84-c049-4c83-930b-2343b96acb62&mKey=081f7976-e4cd-4f3d-a0af-e8387992a658 (2009)."},{"key":"330_CR247","doi-asserted-by":"crossref","unstructured":"De Muynck, L. & Van Damme, P. In Frontiers in Clinical Drug Research \u2013 Alzheimer Disorders (ed. Atta-ur-Rahman) 231\u2013291 (Bentham Books, 2015).","DOI":"10.2174\/9781681080680115030007"},{"key":"330_CR248","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02149160 (2016)."},{"key":"330_CR249","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.trci.2017.08.002","volume":"3","author":"SJ Sha","year":"2017","unstructured":"Sha, S. J. et al. An 8-week, open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations. Alzheimers Dement. 3, 507\u2013512 (2017).","journal-title":"Alzheimers Dement."},{"key":"330_CR250","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/14728222.2018.1487951","volume":"22","author":"D Galimberti","year":"2018","unstructured":"Galimberti, D., Fenoglio, C. & Scarpini, E. Progranulin as a therapeutic target for dementia. Expert Opin. Ther. Targets 22, 579\u2013585 (2018).","journal-title":"Expert Opin. Ther. Targets"},{"key":"330_CR251","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.neuron.2010.09.034","volume":"68","author":"F Hu","year":"2010","unstructured":"Hu, F. et al. Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron 68, 654\u2013667 (2010).","journal-title":"Neuron"},{"key":"330_CR252","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/hmg\/ddt534","volume":"23","author":"WC Lee","year":"2014","unstructured":"Lee, W. C. et al. Targeted manipulation of the sortilin-progranulin axis rescues progranulin haploinsufficiency. Hum. Mol. Genet. 23, 1467\u20131478 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"330_CR253","unstructured":"Alector Announces Data from On-going Phase 1b Trial Demonstrating that AL001 Reverses Progranulin Deficiency in Frontotemporal Dementia Patients. BioSpace https:\/\/www.biospace.com\/article\/-alector-announces-data-from-on-going-phase-1b-trial-demonstrating-that-al001-reverses-progranulin-deficiency-in-frontotemporal-dementia-patients\/ (2019)."},{"key":"330_CR254","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03987295 (2019)."},{"key":"330_CR255","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41582-019-0231-z","volume":"15","author":"F Bright","year":"2019","unstructured":"Bright, F. et al. Neuroinflammation in frontotemporal dementia. Nat. Rev. Neurol. 15, 540\u2013555 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"330_CR256","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1126\/science.1199214","volume":"332","author":"W Tang","year":"2011","unstructured":"Tang, W. et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 332, 478\u2013484 (2011).","journal-title":"Science"},{"key":"330_CR257","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13024-016-0114-3","volume":"11","author":"CJ Holler","year":"2016","unstructured":"Holler, C. J. et al. Trehalose upregulates progranulin expression in human and mouse models of GRN haploinsufficiency: a novel therapeutic lead to treat frontotemporal dementia. Mol. Neurodegener. 11, 46 (2016).","journal-title":"Mol. Neurodegener."},{"key":"330_CR258","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.bcp.2015.07.016","volume":"97","author":"SS Minami","year":"2015","unstructured":"Minami, S. S. et al. Reducing inflammation and rescuing FTD-related behavioral deficits in progranulin-deficient mice with \u03b17 nicotinic acetylcholine receptor agonists. Biochem. Pharmacol. 97, 454\u2013462 (2015).","journal-title":"Biochem. Pharmacol."},{"key":"330_CR259","unstructured":"Prevail Therapeutics Announces FDA Orphan Drug Designation Granted to PR006 for the Treatment of Patients with Frontotemporal Dementia with a GRN Mutation. BioSpace https:\/\/www.biospace.com\/article\/releases\/prevail-therapeutics-announces-fda-orphan-drug-designation-granted-to-pr006-for-the-treatment-of-patients-with-frontotemporal-dementia-with-a-grn-mutation\/ (2019)."},{"key":"330_CR260","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/humu.22244","volume":"34","author":"J Van Der Zee","year":"2013","unstructured":"Van Der Zee, J. et al. A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum. Mutat. 34, 363\u2013373 (2013).","journal-title":"Hum. Mutat."},{"key":"330_CR261","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1126\/science.aaf7791","volume":"353","author":"NJ Kramer","year":"2016","unstructured":"Kramer, N. J. et al. Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. Science 353, 708\u2013712 (2016).","journal-title":"Science"},{"key":"330_CR262","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.neuron.2013.10.015","volume":"80","author":"CJ Donnelly","year":"2013","unstructured":"Donnelly, C. J. et al. RNA toxicity from the ALS\/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 80, 415\u2013428 (2013).","journal-title":"Neuron"},{"key":"330_CR263","doi-asserted-by":"publisher","first-page":"208ra149","DOI":"10.1126\/scitranslmed.3007529","volume":"5","author":"D Sareen","year":"2013","unstructured":"Sareen, D. et al. Targeting RNA foci in iPSC derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci. Transl Med. 5, 208ra149 (2013).","journal-title":"Sci. Transl Med."},{"key":"330_CR264","doi-asserted-by":"publisher","first-page":"E4530","DOI":"10.1073\/pnas.1318835110","volume":"19","author":"C Lagier-Tourenne","year":"2013","unstructured":"Lagier-Tourenne, C. et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl Acad. Sci. USA 19, E4530\u2013E4539 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"330_CR265","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.chembiol.2015.09.016","volume":"22","author":"J Hu","year":"2015","unstructured":"Hu, J. et al. Engineering duplex RNAs for challenging targets: recognition of GGGGCC\/CCCCGG repeats at the ALS\/FTD C9orf72 locus. Chem. Biol. 22, 1505\u20131511 (2015).","journal-title":"Chem. Biol."},{"key":"330_CR266","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.001","volume":"16","author":"R Martier","year":"2019","unstructured":"Martier, R. et al. Targeting RNA-mediated toxicity in C9orf72 ALS and\/or FTD by RNAi-based gene therapy. Mol. Ther. Nucleic Acids 16, 26\u201337 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"330_CR267","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12143","volume":"7","author":"K Kapeli","year":"2016","unstructured":"Kapeli, K. et al. Distinct and shared functions of ALS-associated proteins TDP-43, FUS and TAF15 revealed by multisystem analyses. Nat. Commun. 7, 12143 (2016).","journal-title":"Nat. Commun."},{"key":"330_CR268","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s11064-015-1758-z","volume":"41","author":"S Fujii","year":"2016","unstructured":"Fujii, S. et al. Treatment with a global methyltransferase inhibitor induces the intranuclear aggregation of ALS-linked FUS mutant in vitro. Neurochem. Res. 41, 826\u2013835 (2016).","journal-title":"Neurochem. Res."},{"key":"330_CR269","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02372773 (2019)."},{"key":"330_CR270","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02365922 (2019)."},{"key":"330_CR271","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02590276 (2016)."},{"key":"330_CR272","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02327845 (2019)."},{"key":"330_CR273","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/jnnp-2018-318603","volume":"90","author":"P Desmarais","year":"2019","unstructured":"Desmarais, P. et al. Therapeutic trial design for frontotemporal dementia and related disorders. J. Neurol. Neurosurg. Psychiatry 90, 412\u2013442 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"330_CR274","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13195-018-0345-3","volume":"10","author":"E Semler","year":"2018","unstructured":"Semler, E. et al. A language-based sum score for the course and therapeutic intervention in primary progressive aphasia. Alzheimers Res. Ther. 10, 41 (2018).","journal-title":"Alzheimers Res. Ther."},{"key":"330_CR275","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/brain\/awy319","volume":"142","author":"AM Staffaroni","year":"2019","unstructured":"Staffaroni, A. M. et al. Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials. Brain 142, 443\u2013459 (2019).","journal-title":"Brain"},{"key":"330_CR276","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1002\/acn3.643","volume":"5","author":"PA Ljubenkov","year":"2018","unstructured":"Ljubenkov, P. A. et al. Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. Ann. Clin. Transl Neurol. 5, 1250\u20131263 (2018).","journal-title":"Ann. Clin. Transl Neurol."},{"key":"330_CR277","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2217\/nmt-2019-0006","volume":"9","author":"P Modrego","year":"2019","unstructured":"Modrego, P. & Lobo, A. A good marker does not mean a good target for clinical trials in Alzheimer\u2019s disease: the amyloid hypothesis questioned. Neurodegener. Dis. Manag. 9, 119\u2013121 (2019).","journal-title":"Neurodegener. Dis. Manag."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41582-020-0330-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41582-020-0330-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41582-020-0330-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:12:45Z","timestamp":1684620765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-020-0330-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,23]]},"references-count":277,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["330"],"URL":"https:\/\/doi.org\/10.1038\/s41582-020-0330-x","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,23]]},"assertion":[{"value":"14 February 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.P.I. is an employee at Chiesi Farmaceutici and has developed and is co-inventor of patents on anti-Alzheimer disease drugs; he does not hold stock options. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}